Applied Story

<div class='circular--portrait' style='background:#FF01C9;color: #E6E6FA;font-size:4em;'>AD</div>
APDN -- USA Stock  

USD 5.94  0.02  0.34%

Applied DNA Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 1.58. Current Ratio is expected to rise to 1.13 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (7.8 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will outline Applied DNA. We will look into reasons why it is still very possible for the company to generate above-average returns. The company barely shadows the market. We can now inspect Applied as a potential investment option for your portfolios.
Published over three months ago
View all stories for Applied Dna | View All Stories
Are Applied DNA (NASDAQ:APDN) conflicting forward indicators contributing to the latest slide?
We provide trade advice to complement the prevailing expert consensus on Applied DNA Sciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. Applied DNA dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Applied Dna income statement, its balance sheet, and the statement of cash flows. Potential Applied Dna investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Applied Dna investors may use each financial statement separately, they are all related. The changes in Applied Dna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Applied Dna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Applied Dna fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Applied Dna performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Applied Dna shares is the value that is considered the true value of the share. If the intrinsic value of Applied is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Applied Dna.
Please read more on our fundamental analysis page.

Are Applied Dna Earnings Expected to grow?

The future earnings power of Applied Dna involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Applied Dna factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Applied Dna stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Applied expected earnings.

How Applied utilizes its cash?

To perform a cash flow analysis of Applied Dna, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Applied Dna is receiving and how much cash it distributes out in a given period. The Applied Dna cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Applied Dna Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (10.82 Million)

Applied Dna Gross Profit

Applied Dna Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Applied Dna previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Applied Dna Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Applied Dna exotic insider transaction detected

Legal trades by Applied Dna insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Applied insider trading alert for general transaction of incentive stock option (right to buy) by Shorrock Clay, Chief Legal Officer, on 5th of April 2021. This event was filed by Applied Dna Sciences Inc with SEC on 2021-04-05. Initial filing of beneficial ownership - SEC Form 3 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Applied Dna valued adequately by the market?

Applied DNA Sciences reported the previous year's revenue of 3.29 M. Net Loss for the year was (10.44 M) with profit before overhead, payroll, taxes, and interest of 4.51 M.

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Applied DNA has an asset utilization ratio of 21.14 percent. This suggests that the company is making $0.21 for each dollar of assets. An increasing asset utilization means that Applied DNA Sciences is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
2.5 M
Assets Non Current
1.9 M
Goodwill
1.2 M
Current Assets2.53 Million45.35
Assets Non Current1.87 Million33.4
Goodwill1.19 Million21.25

Will Applied DNA latest rise continue?

Applied DNA latest mean deviation surges over 2.77. Applied DNA Sciences exhibits very low volatility with skewness of 0.71 and kurtosis of 1.65. However, we advise investors to further study Applied DNA Sciences technical indicators to make sure all market info is available and is reliable.

Our Final Perspective on Applied DNA

Whereas other entities in the security & protection services industry are either recovering or due for a correction, Applied DNA may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Applied valuation and our trade advice on Applied DNA is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Applied DNA.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Applied Dna Scns. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com